ライフサイエンスコーパス: sPLA2-IIA

1 sPLA2-IIA also bound to alpha4beta1.

2 The type IIA secretory phospholipase A2 (sPLA2-IIA) is a host protein endowed with antibacterial

3 f human group IIA secreted phospholipase A2 (sPLA2-IIA), a bactericidal enzyme induced during acute i

4 Group IIA secretory phospholipase A2 (sPLA2-IIA), released during inflammation, is increased i

5 Independent of its catalytic activity, sPLA2-IIA induces pro-inflammatory signals in a receptor

6 ment significantly attenuated PLA2 activity, sPLA2-IIA mRNA and protein levels, and PtdCho-PLC activi

7 s Ptd-Cho levels by differentially affecting sPLA2-IIA, PtdCho-PLC, and CCTalpha after transient foca

8 individuals, indicating that GBS induces an sPLA2-IIA response in blood during human infection.

9 ) levels yet lower oxLDL/LDL (P = 0.006) and sPLA2-IIA mass (P = 0.04), probably reflecting LD with P

10 sine-mediated inhibition of phagocytosis and sPLA2-IIA expression.

11 ggest that both secretory PLA2 (sPLA2)-V and sPLA2-IIA (encoded, respectively, by the neighbouring PL

12 Because sPLA2-IIA is induced during inflammation, and 12-LO expr

13 o determine whether the relationship between sPLA2-IIA and coronary heart disease is causal.

14 isolates are highly sensitive to killing by sPLA2-IIA but not by human antimicrobial peptides.

15 hydrolysis of the mitochondrial membrane by sPLA2-IIA yields inflammatory mediators (ie, lysophospho

16 6 C allele associated with lower circulating sPLA2-IIA mass (38% to 44%) and sPLA2 enzyme activity (3

17 enzyme activity in inbred strains containing sPLA2-IIA mutations; these strains were also associated

18 ggest that, in the airway, S. aureus escapes sPLA2-IIA-mediated killing through adenosine-mediated in

19 3 and alpha4beta1 may serve as receptors for sPLA2-IIA and mediate pro-inflammatory action of sPLA2-I

20 but catalytic activity is not required, for sPLA2-IIA-induced proliferative signaling.

21 Using transgenic mice that express human sPLA2-IIA, we demonstrate that this enzyme is crucial fo

22 egulation of secretory phospholipase A2 IIA (sPLA2 IIA) mRNA and protein expression, increased PLA2 a

23 substrate of secreted phospholipase A2 IIA (sPLA2-IIA), a phospholipase otherwise specific for bacte

24 d activity of secreted phospholipase A2 IIA (sPLA2-IIA), present in inflammatory fluids, and platelet

25 Secretory phospholipase A2 group IIA (sPLA2-IIA) has been identified as a biomarker of atheros

26 Secretory phospholipase A2 group IIA (sPLA2-IIA) plays an important role in the pathogenesis o

27 However, the role of adenosine in sPLA2-IIA-mediated S. aureus killing by host is still un

28 We identified amino acid residues in sPLA2-IIA (Arg-74 and Arg-100) that are critical for int

29 adenosine production (adsA strain) increased sPLA2-IIA expression in guinea pig airways and was clear

30 S. aureus adsA strain induced sPLA2-IIA expression by alveolar macrophages after phago

31 atory action of sPLA2-IIA, and that integrin-sPLA2-IIA interaction is a novel therapeutic target.

32 previously associated with higher and lower sPLA2-IIA levels respectively.

33 able analysis for MVE for a 1-log unit lower sPLA2-IIA mass was 1.04 (95% CI: 0.96 to 1.13), and diff

34 mice, we show that the coordinated action of sPLA2-IIA and 12-LO promotes inflammatory arthritis.

35 2-IIA and mediate pro-inflammatory action of sPLA2-IIA, and that integrin-sPLA2-IIA interaction is a

36 ought to represent the composite activity of sPLA2-IIA, -V, and -X.

37 veolar macrophages, leading to inhibition of sPLA2-IIA expression.

38 n a previous study, a selective inhibitor of sPLA2-IIA (LY315920NA/S-5920) was well tolerated and app

39 Continuous 7-day infusion of an inhibitor of sPLA2-IIA had no beneficial effect on 28-day all-cause m

40 sive GBS disease contain increased levels of sPLA2-IIA compared with normal sera from healthy individ

41 Higher circulating levels of sPLA2-IIA mass or sPLA2 enzyme activity have been associ

42 nd the catalytically inactive H47Q mutant of sPLA2-IIA induced cell proliferation and ERK1/2 activati

43 found in neutrophils only in the presence of sPLA2-IIA and 12-LO in an in vivo model of autoimmune in

44 Elevated plasma sPLA2-IIA predicts coronary heart disease (CHD) risk, bu

45 Reducing sPLA2-IIA mass is unlikely to be a useful therapeutic go

46 uggests that cytokine induction up-regulates sPLA2 IIA protein expression, resulting in altered lipid

47 er, the M-type receptor is species-specific: sPLA2-IIA binds to the M-type receptor in rodents and ra

48 Here we demonstrated that sPLA2-IIA bound to integrin alphavbeta3 at a high affini

49 vide experimental and clinical evidence that sPLA2-IIA protects humans against GBS infections.

50 We showed that sPLA2-IIA competed with VCAM-1 for binding to alpha4beta

51 t is entirely due to sPLA2-IIA, showing that sPLA2-IIA might represent an important component of humo

52 s11573156, a variant in PLA2G2A encoding the sPLA2-IIA isoenzyme, as an instrumental variable.

53 Consistent with predictions from the sPLA2-IIA gene sequence in inbred strains, we detected l

54 Thus sPLA2-IIA receptors in human have not been established.

55 t the bactericidal effect is entirely due to sPLA2-IIA, showing that sPLA2-IIA might represent an imp

56 own by sequencing to carry variant wild-type sPLA2-IIA alleles.

57 significantly attenuated infarction volume, sPLA2 IIA protein expression, PLA2 activity and signific

58 ypes of PLA2G2A are strongly associated with sPLA2-IIA mass, but not lipid levels.

59 s of intestinal tissues were consistent with sPLA2-IIA activity levels.